Is There a Helium Shortage in 2026? A Lab Procurement Guide

Short answer: not the acute, allocation-driven crisis of 2018-2023 (“Helium Shortage 3.0”), but not a fully resolved market either. Helium supply has diversified and eased since new production came online from Qatar, U.S. Gulf Coast and Wyoming plants, and Russia’s Amur Gas Processing Plant, so most labs are no longer on hard cylinder allocation the way they were a few years ago. What has not gone away is the underlying structural fragility: helium is a nonrenewable byproduct of a small number of natural-gas fields, production is concentrated in a handful of countries and even fewer processing plants, and a single plant outage, pipeline failure, or geopolitical disruption can still tighten supply and move prices within weeks. For a lab manager or procurement officer, “is the shortage over” is the wrong question to plan around — “how exposed is my helium supply to a single point of failure” is the one that actually protects continuity of research and clinical operations.

Why helium shortages happen at all

Helium is chemically inert and the second most abundant element in the universe, but the isotope useful for lab, medical, and industrial applications is not something producers can simply make more of on demand. Three structural facts drive every helium supply cycle:

• It is a byproduct, not a primary product. Almost all commercially recovered helium comes from natural gas fields with unusually high helium content — it is extracted (cryogenically separated) as gas is processed, not drilled for on its own. Producers cannot simply increase helium output in response to helium demand; output is tied to natural gas field economics.
• Production is geographically concentrated. A small number of countries — historically the United States, Qatar, and Algeria, with Russia and more recently Tanzania adding capacity — account for the large majority of global supply. A handful of very large processing plants (rather than many small ones) do most of the liquefaction and purification.
• There is very little buffer inventory in the system. Helium is difficult and expensive to store and transport (it must be kept cold and pressurized, and it leaks through container walls that hold other gases fine), so the market runs closer to just-in-time than most commodities. That makes it unusually sensitive to a single plant going offline for maintenance, a fire, a geopolitical sanction, or a pipeline disruption.

Put together, these are the reasons a resource that is not geologically scarce still produces recurring, real supply shocks — the constraint is processing and logistics concentration, not the amount of helium in the ground.

A brief history: why “Helium Shortage 3.0” is a real phrase

Industry gas suppliers and trade press refer to three distinct shortage episodes since the mid-2000s, each triggered by a different combination of plant outages and geopolitical events layered on top of the structural fragility above:

• Shortage 1.0 (roughly 2006-2007) — plant outages and maintenance shutdowns across major helium sources coincided, tightening supply broadly.
• Shortage 2.0 (roughly 2011-2013) — further plant maintenance and outages, compounded by planned drawdowns tied to the U.S. Federal Helium Reserve’s phased privatization under the Helium Privatization Act of 1996.
• Shortage 3.0 (roughly 2018-2023) — the most severe and prolonged of the three, driven by outages at major Qatari and U.S. plants, the 2017-2021 diplomatic blockade of Qatar (a top global helium exporter) affecting shipping routes, and repeated delays and a fire at Russia’s Amur Gas Processing Plant, which had been expected to become the world’s single largest helium production facility. This is the period most labs and gas distributors remember as hard allocation — suppliers rationing cylinder volumes to existing customers and, in many cases, refusing new accounts.

Each cycle eased as new capacity came online and outages were resolved — not because demand fell.

The “helium shortage myth” — what the debate is actually about

A persistent counter-narrative, sometimes phrased as “the helium shortage is a myth,” argues that helium is not running out and that “shortage” headlines overstate the problem. That framing is partly right and partly a mischaracterization of what suppliers and lab buyers actually mean by the term:

• What’s true: Helium is not close to physical depletion at a planetary scale. New helium-rich gas fields keep being found and brought into production (Tanzania’s Rukwa Basin discoveries being the most significant addition of the past decade), and total identified helium resources have grown, not shrunk, even through the shortage years.
• What the “myth” framing misses: The shortages that affected real labs, hospitals, and party-balloon retailers between 2006 and 2023 were genuine, measurable supply disruptions — cylinder rationing, waitlists, and price spikes actually happened and are documented by gas distributors and trade associations, not just anecdote. The correct statement is not “there is no shortage,” it’s “the shortage is a processing and logistics-concentration problem, not a resource-depletion problem” — a distinction that matters for how you plan procurement (diversify suppliers and reduce consumption per unit of work) rather than how you’d respond to true scarcity (there is nothing a single buyer can do about the total amount of helium in the earth’s crust).

Where helium supply actually stands going into 2026

By most industry accounts, the acute allocation phase of Shortage 3.0 eased through 2024 and 2025 as new supply reached the market: additional Qatari production (Ras Laffan), new and expanded U.S. plants (including Wyoming and Gulf Coast sources), partial ramp-up of Russia’s Amur plant despite ongoing delays, and early Tanzanian production. The U.S. Federal Helium Reserve at the Bush Dome near Amarillo, Texas — historically the world’s largest strategic helium store — completed the privatization mandated by the 1996 Helium Privatization Act, with the federal storage, enrichment, and pipeline system transferred out of direct federal operation; it is no longer the buffer supply of last resort it once was, which shifts more of the market’s stability burden onto private producers and their own storage/logistics decisions.

The practical result for a procurement team: spot availability and pricing volatility are meaningfully better than during the worst of 2018-2023, but the underlying concentration risk described above has not disappeared. A single major plant outage, a shipping disruption affecting Qatari exports, or a further delay at Amur can still tighten regional supply on short notice. Treat the current state as “normalized, not resolved” when you write a procurement or business-continuity plan.

Which lab and clinical equipment is actually exposed

Helium supply risk is not evenly distributed across a research operation — it concentrates wherever helium is a consumable input rather than a one-time fill. The equipment categories most exposed to price and availability swings are:

• NMR spectrometers and MRI magnets — superconducting magnets require liquid helium to stay below their critical temperature; a supply disruption affects both routine top-offs and, in a worst case, the ability to keep a magnet cold (“quench” risk if boil-off cannot be replenished). Most modern systems use recondensing (“zero boil-off”) cryocoolers specifically to reduce this exposure — see the site’s MRI machine cost and ownership requirements guide for the operating-cost implications.
• Gas chromatography carrier gas — helium has long been the default GC carrier gas for its inertness and favorable flow properties; supply tightness during Shortage 3.0 pushed many labs to evaluate hydrogen or nitrogen carrier-gas conversions. See Gas Chromatography: Columns, Carrier Gases and Detectors and GC Detector Types: A Procurement Guide for what a carrier-gas switch actually involves.
• Leak detection — helium mass-spectrometer leak detectors use helium as the tracer gas for vacuum-system and containment integrity testing; this is typically a small-volume, low-exposure use compared to NMR/MRI or GC.
• Welding, calibration, and specialty atmospheres — shielding gas for certain welding processes and carrier/balance gas for some calibration standards, generally a smaller share of a research lab’s total helium spend than the categories above.

Buying helium in the current market: cylinder, bulk, or recovery

How you source helium should scale with how much you consume and how exposed a disruption would leave you:

• Cylinder (compressed gas) is the standard model for low-to-moderate consumption — GC carrier gas at a single instrument, leak-detection use, occasional top-offs. Cylinders are DOT-regulated hazardous materials in transport and require the same handling, storage, and inspection discipline as any compressed gas — see the site’s Compressed Gas Cylinder Safety guide, Compressed Gas Cylinder Inspection Checklist, and the Compressed Gas Cylinder Sizes reference for the size-code conventions suppliers quote against.
• Bulk/dewar liquid helium makes sense once consumption is high enough (typically multiple NMR systems or an MRI operation) to justify on-site liquid storage, delivered on a scheduled or on-demand basis by tanker. Bulk contracts are usually where allocation terms and minimum-purchase clauses matter most during a tight market.
• Recovery and recycling — helium recovery systems that capture and reliquefy NMR boil-off, rather than venting it, cut consumption by a large fraction for facilities running multiple magnets. During Shortage 3.0, recovery investment was one of the few levers a lab could pull that reduced exposure rather than just paying more for the same volume; it remains a legitimate resilience measure even in a looser market, because the capital cost is amortized against avoided future price spikes, not just current spot price.

What to evaluate in a helium supplier or contract

Because helium is a concentrated, disruption-prone market, the right supplier-evaluation questions are different from a generic gas-purchasing checklist. Before signing or renewing a helium contract, confirm:

• Purity grade and certification. Helium is graded by purity (commonly referenced against Compressed Gas Association purity grades, e.g. Grade 4.6/5.0/6.0 helium for analytical and NMR use) — confirm the supplier provides a certificate of analysis per lot, not just a nominal grade on the label, and that the grade matches your instrument manufacturer’s specification (NMR and GC-MS applications are typically far more purity-sensitive than general lab or leak-detection use).
• Allocation history and contract type. Ask directly how the supplier handled allocation during 2018-2023 and whether your account would be treated as new or established in a future tightening — spot-market buyers were consistently the first cut when suppliers rationed. A standing annual or multi-year supply agreement, even at a volume premium, buys priority during the next disruption; a spot/as-needed relationship does not.
• Cylinder condition, tracking, and compliance documentation. Confirm the supplier’s cylinders carry current hydrostatic test dates (see Cylinder Hydrostatic Testing Requirements: DOT/CGA Rules for Labs) and standard valve/fitting configurations (CGA Fittings) — a supplier that can’t produce current test documentation on request is a compliance liability independent of the helium market itself.
• Delivery reliability and geographic diversification. A single-vendor, single-region supply chain concentrates exactly the risk described above. For any helium-dependent instrument where downtime is costly (a clinical MRI, a shared-facility NMR), a documented secondary supplier or backup cylinder reserve is a reasonable business-continuity requirement, not overcaution.
• Recovery/recycling support. Some industrial gas suppliers will buy back or credit recovered helium from a facility’s own recovery system, or partner on recovery-system installation — worth asking about directly if your facility runs multiple superconducting magnets.

General laboratory and medical supply distributors — for example LAC Health, a CASRAI partner — can be one channel for sourcing cylinders and related compliance consumables alongside a dedicated industrial-gas supplier; evaluate any distributor against the same criteria above (documented purity certification, current cylinder test dates, allocation transparency) rather than treating vendor size or convenience as a substitute for those checks.

Building procurement resilience regardless of where the market sits

• Right-size consumption before right-sizing supply. Recovery systems, carrier-gas conversion (hydrogen/nitrogen where analytically valid), and leak-testing procedure reviews all reduce exposure permanently, independent of what the market does next.
• Diversify suppliers and contract types rather than relying on a single vendor or a purely spot-market relationship for anything mission-critical.
• Track allocation risk as a standing item in business-continuity and equipment-risk planning for helium-dependent instrumentation, the same way you would track a single-source reagent or a sole-source service contract.
• Keep compressed-gas compliance current regardless of market tightness — hydrostatic testing, cylinder inspection, and DOT/CGA documentation requirements don’t relax when supply loosens, and a compliance gap discovered during a supply crunch is the worst possible time to find it.

Frequently asked questions

Is there still a helium shortage in 2026?

Not in the acute, hard-allocation sense of 2018-2023 — new supply from Qatar, U.S. plants, and partial Russian production has eased spot availability and pricing volatility. The underlying structural fragility (concentrated production, minimal buffer inventory) remains, so treat the market as normalized rather than fully resolved when planning procurement.

Why is there a helium shortage in the first place?

Helium is recovered as a byproduct of natural gas processing at a small number of fields, production and liquefaction are concentrated in a handful of countries and plants, and there is very little buffer storage in the global supply chain. A single plant outage or geopolitical disruption can tighten supply quickly because there’s no large cushion to absorb it.

Is the helium shortage a myth?

Partly a fair critique, partly a mischaracterization. Helium is not close to physical depletion — new fields keep being discovered and total identified resources have grown. But the documented cylinder rationing, waitlists, and price spikes of 2006-2023 were real, measurable supply disruptions, not manufactured scarcity. The accurate framing is that shortages are a processing/logistics-concentration problem, not a resource-depletion problem.

What caused the global helium shortage of 2018-2023?

Outages at major Qatari and U.S. production plants, the 2017-2021 diplomatic blockade affecting Qatar’s exports, and repeated delays and a fire at Russia’s Amur Gas Processing Plant — layered on top of the market’s already-thin buffer inventory.

Should a lab still worry about helium supply risk if the shortage has eased?

Yes, for any helium-dependent instrument where downtime or a price spike would be costly — an NMR facility, a clinical MRI operation, a GC lab still running helium carrier gas. The structural causes of past shortages (concentrated production, thin buffer inventory) haven’t gone away; only the current acute symptoms have.